Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Maze Therapeutics, Inc.MAZE · Entity 1775 | SVP, Finance | April 01, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Maze Therapeutics, Inc.
Report date April 01, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,965 |
Ending reported balance
After 2026-04-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-04-01 · Exercise / conversion · Acquired 2,500 · Balance 15,465 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Row 2 · 2026-04-01 · Sale · Disposed 2,200 · Balance 13,265 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.85 to $29.82 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Row 3 · 2026-04-01 · Sale · Disposed 300 · Balance 12,965 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $30.50 per share, inclusive. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2034-12-08 | Direct | 33,833 |
Reported balance
After 2026-04-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-01 · Exercise / conversion · Disposed 2,500 · Balance 33,833 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.85 to $29.82 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $30.50 per share, inclusive.
F4: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 2, 2026 16:06 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050422-26-000012 · form4-04022026_080443.xml · derivative · entry 4 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,833 Underlying: Common Stock · 2,500 shares Expires 2034-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 16:06 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 300 | $30.34 | $9,101.01 |
DisclosureSEC source: 0002050422-26-000012 · form4-04022026_080443.xml · nonDerivative · entry 3 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,965 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $30.50 per share, inclusive. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 16:06 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 2,200 | $29.32 | $64,509.94 |
DisclosureSEC source: 0002050422-26-000012 · form4-04022026_080443.xml · nonDerivative · entry 2 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,265 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.85 to $29.82 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 16:06 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 2,500 | $10.42 | $26,050.00 |
DisclosureSEC source: 0002050422-26-000012 · form4-04022026_080443.xml · nonDerivative · entry 1 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantRestricted Stock Units · Derivative | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002050422-26-000010 · form4-03032026_090334.xml · derivative · entry 6 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F7 · derivative.exercise_date: The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date. F8 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $45.61 | $0.00 |
DisclosureSEC source: 0002050422-26-000010 · form4-03032026_090334.xml · derivative · entry 5 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-03-01 F5 · derivative.exercise_date: The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050422-26-000010 · form4-03032026_090334.xml · derivative · entry 4 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,333 Underlying: Common Stock · 5,000 shares Expires 2034-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 3,700 | $45.47 | $168,236.78 |
DisclosureSEC source: 0002050422-26-000010 · form4-03032026_090334.xml · nonDerivative · entry 3 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,965 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.03 to $45.99 per share, inclusive. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 1,300 | $44.44 | $57,773.82 |
DisclosureSEC source: 0002050422-26-000010 · form4-03032026_090334.xml · nonDerivative · entry 2 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,665 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.01 to $44.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 5,000 | $10.42 | $52,100.00 |
DisclosureSEC source: 0002050422-26-000010 · form4-03032026_090334.xml · nonDerivative · entry 1 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 16:23 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 156 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050422-26-000008 · form4-02042026_090208.xml · derivative · entry 7 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,333 Underlying: Common Stock · 156 shares Expires 2034-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F5 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 16:23 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,844 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050422-26-000008 · form4-02042026_090208.xml · derivative · entry 6 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,025 Underlying: Common Stock · 4,844 shares Expires 2032-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2026. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 16:23 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 736 | $46.63 | $34,321.37 |
DisclosureSEC source: 0002050422-26-000008 · form4-02042026_090208.xml · nonDerivative · entry 5 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,965 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.365 to $47.23 per share, inclusive. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 16:23 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 4,064 | $46.03 | $187,067.95 |
DisclosureSEC source: 0002050422-26-000008 · form4-02042026_090208.xml · nonDerivative · entry 4 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,701 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.345 to $46.34 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 16:23 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 200 | $44.15 | $8,830.00 |
DisclosureSEC source: 0002050422-26-000008 · form4-02042026_090208.xml · nonDerivative · entry 3 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,765 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 16:23 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 156 | $10.42 | $1,625.52 |
DisclosureSEC source: 0002050422-26-000008 · form4-02042026_090208.xml · nonDerivative · entry 2 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 16:23 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 4,844 | $10.42 | $50,474.48 |
DisclosureSEC source: 0002050422-26-000008 · form4-02042026_090208.xml · nonDerivative · entry 1 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 16:10 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,503 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050422-26-000005 · form4-01262026_090133.xml · derivative · entry 5 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,869 Underlying: Common Stock · 2,503 shares Expires 2032-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on March 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 16:10 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,497 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050422-26-000005 · form4-01262026_090133.xml · derivative · entry 4 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 486 Underlying: Common Stock · 2,497 shares Expires 2031-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2021, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 16:10 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 5,000 | $45.52 | $227,612.00 |
DisclosureSEC source: 0002050422-26-000005 · form4-01262026_090133.xml · nonDerivative · entry 3 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,965 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.93 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 16:10 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 2,503 | $10.42 | $26,081.26 |
DisclosureSEC source: 0002050422-26-000005 · form4-01262026_090133.xml · nonDerivative · entry 2 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 16:10 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 2,497 | $10.42 | $26,018.74 |
DisclosureSEC source: 0002050422-26-000005 · form4-01262026_090133.xml · nonDerivative · entry 1 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:30 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,796 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050422-26-000003 · form4-01062026_090124.xml · derivative · entry 6 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,983 Underlying: Common Stock · 4,796 shares Expires 2031-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F5 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 1, 2025. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:30 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 204 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050422-26-000003 · form4-01062026_090124.xml · derivative · entry 5 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,377 Underlying: Common Stock · 204 shares Expires 2032-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on November 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:30 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 2,595 | $39.57 | $102,681.30 |
DisclosureSEC source: 0002050422-26-000003 · form4-01062026_090124.xml · nonDerivative · entry 4 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,965 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.15 to $39.99 per share, inclusive. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:30 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 2,405 | $38.70 | $93,072.30 |
DisclosureSEC source: 0002050422-26-000003 · form4-01062026_090124.xml · nonDerivative · entry 3 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,560 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.15 to $39.14 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:30 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 4,796 | $10.42 | $49,974.32 |
DisclosureSEC source: 0002050422-26-000003 · form4-01062026_090124.xml · nonDerivative · entry 2 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:30 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 204 | $10.42 | $2,125.68 |
DisclosureSEC source: 0002050422-26-000003 · form4-01062026_090124.xml · nonDerivative · entry 1 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,605 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050422-25-000007 · form4-12312025_091203.xml · derivative · entry 11 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,581 Underlying: Common Stock · 2,605 shares Expires 2032-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F7 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on November 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,395 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050422-25-000007 · form4-12312025_091203.xml · derivative · entry 10 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 2,395 shares Expires 2031-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F5 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2025. Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 5,000 | $40.08 | $200,407.00 |
DisclosureSEC source: 0002050422-25-000007 · form4-12312025_091203.xml · nonDerivative · entry 7 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,965 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.36 per share, inclusive. Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 2,605 | $10.42 | $27,144.10 |
DisclosureSEC source: 0002050422-25-000007 · form4-12312025_091203.xml · nonDerivative · entry 6 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 2,395 | $10.42 | $24,955.90 |
DisclosureSEC source: 0002050422-25-000007 · form4-12312025_091203.xml · nonDerivative · entry 5 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,876 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050422-25-000007 · form4-12312025_091203.xml · derivative · entry 9 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,834 Underlying: Common Stock · 9,876 shares Expires 2034-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F6 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 124 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050422-25-000007 · form4-12312025_091203.xml · derivative · entry 8 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,396 Underlying: Common Stock · 124 shares Expires 2031-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F5 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2025. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 600 | $41.16 | $24,694.98 |
DisclosureSEC source: 0002050422-25-000007 · form4-12312025_091203.xml · nonDerivative · entry 4 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,965 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.04 to $41.29 per share, inclusive. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 9,400 | $40.54 | $381,071.30 |
DisclosureSEC source: 0002050422-25-000007 · form4-12312025_091203.xml · nonDerivative · entry 3 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,565 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.04 to $40.94 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 9,876 | $10.42 | $102,907.92 |
DisclosureSEC source: 0002050422-25-000007 · form4-12312025_091203.xml · nonDerivative · entry 2 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 16:20 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 124 | $10.42 | $1,292.08 |
DisclosureSEC source: 0002050422-25-000007 · form4-12312025_091203.xml · nonDerivative · entry 1 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 16:23 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantRestricted Stock Units · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002050422-25-000004 · form4-09242025_080910.xml · derivative · entry 1 Bachrodt Amy · CIK 0002050422 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award shall vest as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.